JP2018501287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501287A5 JP2018501287A5 JP2017536301A JP2017536301A JP2018501287A5 JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5 JP 2017536301 A JP2017536301 A JP 2017536301A JP 2017536301 A JP2017536301 A JP 2017536301A JP 2018501287 A5 JP2018501287 A5 JP 2018501287A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- independently selected
- heterocyclyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C1CN(C)CCCC1 Chemical compound C*C1CN(C)CCCC1 0.000 description 6
- ORTAXXZJVCPZJF-UHFFFAOYSA-N CC(C)N1CC(C)CCC1 Chemical compound CC(C)N1CC(C)CCC1 ORTAXXZJVCPZJF-UHFFFAOYSA-N 0.000 description 1
- VSOUMKMNUXEUSD-ALCCZGGFSA-N CC(C1)CN(C)CC(/C=C\C)=C1C=C Chemical compound CC(C1)CN(C)CC(/C=C\C)=C1C=C VSOUMKMNUXEUSD-ALCCZGGFSA-N 0.000 description 1
- LFFZOLXDIOABNK-UHFFFAOYSA-N CC(C1)CN(C)CC1c1ccccc1 Chemical compound CC(C1)CN(C)CC1c1ccccc1 LFFZOLXDIOABNK-UHFFFAOYSA-N 0.000 description 1
- KAOJZDBVQFDETF-UHFFFAOYSA-N CC(CCC1)CN1C1COC1 Chemical compound CC(CCC1)CN1C1COC1 KAOJZDBVQFDETF-UHFFFAOYSA-N 0.000 description 1
- JOMNTGWLHKQFDP-UHFFFAOYSA-N CC(CCC1)CN1c1ccccn1 Chemical compound CC(CCC1)CN1c1ccccn1 JOMNTGWLHKQFDP-UHFFFAOYSA-N 0.000 description 1
- TVSMLBGFGKLKOO-UHFFFAOYSA-N CC1CCN(C)CC1 Chemical compound CC1CCN(C)CC1 TVSMLBGFGKLKOO-UHFFFAOYSA-N 0.000 description 1
- KHJRPDXBGMNIOL-UHFFFAOYSA-N CC1CN(C)CCCCC1 Chemical compound CC1CN(C)CCCCC1 KHJRPDXBGMNIOL-UHFFFAOYSA-N 0.000 description 1
- KCXFAJMKBCGTRV-UHFFFAOYSA-N CC1CN(Cc(c(F)ccc2)c2F)CCC1 Chemical compound CC1CN(Cc(c(F)ccc2)c2F)CCC1 KCXFAJMKBCGTRV-UHFFFAOYSA-N 0.000 description 1
- BLHUIUXQDPKECV-UHFFFAOYSA-N CC1CN(Cc(cc2)ccc2-[n]2cncc2)CCC1 Chemical compound CC1CN(Cc(cc2)ccc2-[n]2cncc2)CCC1 BLHUIUXQDPKECV-UHFFFAOYSA-N 0.000 description 1
- MUISTLXLYGOELT-UHFFFAOYSA-N CC1CN(Cc(cc2)ccc2N(C)C)CCC1 Chemical compound CC1CN(Cc(cc2)ccc2N(C)C)CCC1 MUISTLXLYGOELT-UHFFFAOYSA-N 0.000 description 1
- FFTYZXRGYXVOEJ-UHFFFAOYSA-N CC1CN(Cc2c[nH]cn2)CCC1 Chemical compound CC1CN(Cc2c[nH]cn2)CCC1 FFTYZXRGYXVOEJ-UHFFFAOYSA-N 0.000 description 1
- PRZCNJXTNAIXJL-UHFFFAOYSA-N CC1CN(Cc2ccccc2)CCCC1 Chemical compound CC1CN(Cc2ccccc2)CCCC1 PRZCNJXTNAIXJL-UHFFFAOYSA-N 0.000 description 1
- WWVZKPBPGCLMOG-UHFFFAOYSA-N CC1CN(Cc2ccccc2N2CCOCC2)CCC1 Chemical compound CC1CN(Cc2ccccc2N2CCOCC2)CCC1 WWVZKPBPGCLMOG-UHFFFAOYSA-N 0.000 description 1
- RNKQHDVQCSVOGW-UHFFFAOYSA-N CC1CN(Cc2cncnc2)CCC1 Chemical compound CC1CN(Cc2cncnc2)CCC1 RNKQHDVQCSVOGW-UHFFFAOYSA-N 0.000 description 1
- UIAPUMMNWHJDPP-UHFFFAOYSA-N CC1CN(Cc2nc(-c(cc3)ccc3Cl)n[o]2)CCC1 Chemical compound CC1CN(Cc2nc(-c(cc3)ccc3Cl)n[o]2)CCC1 UIAPUMMNWHJDPP-UHFFFAOYSA-N 0.000 description 1
- FZJMIEMOFJMEFG-UHFFFAOYSA-N CC1CN(Cc2nc(C)c(C)[nH]2)CCC1 Chemical compound CC1CN(Cc2nc(C)c(C)[nH]2)CCC1 FZJMIEMOFJMEFG-UHFFFAOYSA-N 0.000 description 1
- RANIOUARVJHRLJ-UHFFFAOYSA-N CC1CN(Cc2ncc[nH]2)CCC1 Chemical compound CC1CN(Cc2ncc[nH]2)CCC1 RANIOUARVJHRLJ-UHFFFAOYSA-N 0.000 description 1
- CJBSMZBBZLGYAY-UHFFFAOYSA-N CC1CN(Cc2ncc[n]2C)CCC1 Chemical compound CC1CN(Cc2ncc[n]2C)CCC1 CJBSMZBBZLGYAY-UHFFFAOYSA-N 0.000 description 1
- AWGFYHPTHGCSDM-UHFFFAOYSA-N CC1CN(Cc2ncccc2)CCC1 Chemical compound CC1CN(Cc2ncccc2)CCC1 AWGFYHPTHGCSDM-UHFFFAOYSA-N 0.000 description 1
- KTNBEPXTYFTMMY-UHFFFAOYSA-N Cc1cncc(CN(CCC2)CC2[IH]C)c1 Chemical compound Cc1cncc(CN(CCC2)CC2[IH]C)c1 KTNBEPXTYFTMMY-UHFFFAOYSA-N 0.000 description 1
- FXFRHGUUYYJUAV-UHFFFAOYSA-N Clc1cc(CN(CCC2)CC2I)cc(Cl)c1 Chemical compound Clc1cc(CN(CCC2)CC2I)cc(Cl)c1 FXFRHGUUYYJUAV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101953P | 2015-01-09 | 2015-01-09 | |
| US62/101,953 | 2015-01-09 | ||
| PCT/US2016/012659 WO2016112298A1 (en) | 2015-01-09 | 2016-01-08 | Pyridazinone derivatives and their use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501287A JP2018501287A (ja) | 2018-01-18 |
| JP2018501287A5 true JP2018501287A5 (https=) | 2019-01-31 |
| JP6659703B2 JP6659703B2 (ja) | 2020-03-04 |
Family
ID=55299747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536301A Expired - Fee Related JP6659703B2 (ja) | 2015-01-09 | 2016-01-08 | ピリダジノン誘導体および癌の処置におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10239861B2 (https=) |
| EP (1) | EP3242874B1 (https=) |
| JP (1) | JP6659703B2 (https=) |
| CN (1) | CN107406429B (https=) |
| WO (1) | WO2016112298A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN107074824B (zh) | 2014-09-05 | 2021-01-08 | 基因泰克公司 | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 |
| KR102194536B1 (ko) * | 2019-06-10 | 2020-12-23 | 연세대학교 산학협력단 | 타목시펜의 반응성 예측용 조성물 |
| CN112824381B (zh) * | 2019-11-21 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种哌啶胺的制备方法 |
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2022076735A1 (en) * | 2020-10-09 | 2022-04-14 | Regents Of The University Of Minnesota | Inhibitors of the bromodomain phd finger transcription factor (bptf) as anti-cancer agents |
| KR102766287B1 (ko) * | 2021-10-15 | 2025-02-12 | 고려대학교 산학협력단 | 피리다벤을 포함하는 자궁내막 세포, 영양막 세포 또는 고환 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JP2025530801A (ja) | 2022-09-02 | 2025-09-17 | オーロン セラピューティクス，インコーポレーテッド | 増殖性障害を処置するためのｋａｔ２分解誘導薬としてのピリダジノン誘導体 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| FR2707294B1 (fr) | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| CN1905873A (zh) * | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| SG154433A1 (en) | 2004-06-30 | 2009-08-28 | Janssen Pharmaceutica Nv | Phthalazine derivatives as parp inhibitors |
| JP2012131708A (ja) * | 2009-04-28 | 2012-07-12 | Nissan Chem Ind Ltd | ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤 |
| JP2013528180A (ja) | 2010-05-28 | 2013-07-08 | ジーイー・ヘルスケア・リミテッド | 放射性標識化合物及びその製造方法 |
| UY35103A (es) | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| JP2016507496A (ja) * | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| JP2016519672A (ja) * | 2013-03-15 | 2016-07-07 | ジェネンテック， インコーポレイテッド | ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療 |
| CN107074824B (zh) | 2014-09-05 | 2021-01-08 | 基因泰克公司 | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
-
2016
- 2016-01-08 EP EP16702831.5A patent/EP3242874B1/en active Active
- 2016-01-08 JP JP2017536301A patent/JP6659703B2/ja not_active Expired - Fee Related
- 2016-01-08 WO PCT/US2016/012659 patent/WO2016112298A1/en not_active Ceased
- 2016-01-08 CN CN201680014128.0A patent/CN107406429B/zh not_active Expired - Fee Related
-
2017
- 2017-07-07 US US15/643,801 patent/US10239861B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501287A5 (https=) | ||
| JP2019516757A5 (https=) | ||
| JP2017530176A5 (https=) | ||
| JP2017533250A5 (https=) | ||
| JP2017526696A5 (https=) | ||
| JP2019516759A5 (https=) | ||
| JP2017533249A5 (https=) | ||
| JP2017537100A5 (https=) | ||
| JP2018510851A5 (https=) | ||
| JP2017533248A5 (https=) | ||
| JP2017525740A5 (https=) | ||
| JP2017530984A5 (https=) | ||
| JP2024521706A5 (https=) | ||
| JP2012510990A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| CN107250149A (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
| JP2013510123A5 (https=) | ||
| JP2016506916A5 (https=) | ||
| JP2016529312A5 (https=) | ||
| JP2015500209A5 (https=) | ||
| JP2017510641A5 (https=) | ||
| HRP20171154T1 (hr) | Kristalni inhibitori bromodomene | |
| JP2018529742A5 (https=) | ||
| JP2016516020A5 (https=) | ||
| JP2017502092A5 (https=) |